UNITAID
Global Health Campus, Chemin du Pommier 40, 5th floor, Le Grand-Saconnex, Geneva, 1218, Switzerland
Overview
Unitaid connects innovators who develop better health products with people who need them the most.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- ZYOMYX
Led · Equity · Mar 2014
Zyomyx has developed MyT4, a quantitative, service-free point-of-care CD4 test that provides results in 10 minutes from a finger‑prick. The MyT4 delivers results equivalent to lab-based flow cytometry and received a CE Mark in December 2013; it is commercially available. The test requires no complex instrumentation or maintenance, lowering adoption costs versus instrument-based platforms and enabling decentralization of HIV testing. Zyomyx's platform technology aims to move laboratory tests for cells, proteins and infectious agents to the point of care, and the company is building an expanding pipeline including diagnostics for antibiotic resistance. To support commercial introduction and scale-up, Zyomyx received a US$7.5 million award from UNITAID to fund field evaluations, training for national HIV programs, and regulatory filings. The company is privately held and based in Fremont, California.
Team
No current team members are available.